Cancer Patient Beliefs and Attitudes Regarding Immune Checkpoint Inhibitor Therapy

Authors

Nedal Darwish, Arnot Ogden Medical CenterFollow
Delaney C. Stuhr, Lake Erie College of Osteopathic MedicineFollow
Haily M. Datz, Lake Erie College of Osteopathic MedicineFollow
Halima Bakillah, Arnot Ogden Medical CenterFollow
Tenzin Tseky, Arnot Ogden Medical CenterFollow
Mohamed Manaa, Arnot Ogden Medical CenterFollow
Serge Dauphin, University of Rochester Medical CenterFollow

Author Credentials

Nedal Darwish MD, Delaney Colette Stuhr BA, Haily Monique Datz BS, Halima Bakillah MD, Mohammed Manaa MD, Tenzin Tseky MD, Sere Dauphin MD

Author ORCID Identifier

0000-0003-1877-8921

Abstract

The development and widespread use of immune checkpoint inhibitors (ICIs) have advanced the field of oncology in a short period of time. Despite this, patient perception regarding this new medication class has not been adequately assessed, which may affect treatment decisions and adherence. The Belief about Medicines Questionnaire (BMQ) is a validated survey composed of 18 questions which analyzes patient’s beliefs about the necessity of prescribed medication and concern about the potential adverse events caused by the medication. General medication overuse and harm are also determined. This is the first study to utilize the BMQ for patients on ICI therapy.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Recommended Citation

Darwish N, Stuhr DC, Datz HM, Bakillah H, Tseky T, Manaa M, Dauphin S. Cancer Patient Beliefs and Attitudes Regarding Immune Checkpoint Inhibitor Therapy. Advances in Clinical Medical Research and Healthcare Delivery. 2022; 2(3). doi: 10.53785/2769-2779.1110.

Publisher Note

All articles published in ACMRHD are distributed with a Creative Commons CC BY-NC 4.0 license. Under this license, authors hold the copyright to their work and have the right to share or adapt the article with no restrictions, as long as the author(s) and source are cited, and the use is for noncommercial purposes. This policy went into effect November 1, 2023, and applies retroactively to all articles published in ACMRHD prior to that date, as well.